title: Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.
abstract: Riociguat is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Some patients have difficulty swallowing tablets; therefore, 2 randomized, nonblinded, crossover studies compared the relative bioavailability of riociguat oral suspensions and immediate-release (IR) tablet and of crushed-tablet preparations versus whole IR tablet. In study 1, 30 healthy subjects received 5 single riociguat doses: 0.3 and 2.4 mg (0.15 mg/mL suspensions), 0.15 mg (0.03 mg/mL), and 1.0 mg (whole IR tablet) under fasted conditions and 2.4 mg (0.15 mg/mL) after a high-fat, high-calorie American-style breakfast. In study 2, 25 healthy men received 4 single 2.5-mg doses: whole IR tablet and crushed IR tablet suspended in applesauce and water, respectively, under fasted conditions, and whole IR tablet after a continental breakfast. In study 1, dose-normalized pharmacokinetics of riociguat oral suspensions and 1.0-mg whole IR tablet were similar in fasted conditions; 90% confidence intervals for riociguat area under the curve (AUC) to dose and mean maximum concentration (C max) to dose were within bioequivalence criteria. After food, dose-normalized AUC and C max decreased by 15% and 38%, respectively. In study 2, riociguat exposure was similar for all preparations; AUC ratios for crushed-IR-tablet preparations to whole IR tablet were within bioequivalence criteria. The C max increased by 17% for crushed IR tablet in water versus whole IR tablet. Food intake decreased C max of the whole tablet by 16%, with unaltered AUC versus fasted conditions. Riociguat bioavailability was similar between the oral suspensions and the whole IR tablet; exposure was similar between whole IR tablet and crushed-IR-tablet preparations. Minor food effects were observed. Results suggest that riociguat formulations are interchangeable.
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Soundos
authors.initials: S
authors.lastname: Saleh
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Reiner
authors.initials: R
authors.lastname: Frey
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Corina
authors.initials: C
authors.lastname: Becker
authors.affiliation: Global Biostatistics, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Sigrun
authors.initials: S
authors.lastname: Unger
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Wensing
authors.affiliation: Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Mück
keywords: bioequivalence; food effect; formulation; pulmonary hypertension; soluble guanylate cyclase stimulator